Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398972 | 0.88 | ALDH1A1 (0.55) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL22849511 | 0.88 | ALDH1A1 (0.55) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL17803036 | 0.86 | AGTR2 (0.47) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL1913003 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CTSLCTSBCTSKGAA | |
| SCHEMBL757461 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CTSLCTSBCTSKGAA | |
| SCHEMBL16398138 | 0.85 | TSHR (0.57) | CTSLCTSBCTSKAGTR2GAA | |
| SCHEMBL22835418 | 0.85 | AGTR2 (0.46) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL22849113 | 0.85 | AGTR2 (0.46) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL16398139 | 0.85 | TSHR (0.57) | CTSLCTSBCTSKAGTR2GAA | |
| SCHEMBL12093795 | 0.85 | ALDH1A1 (0.41) | ALDH1A1CTSLCTSBCTSKAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CTSL 941/4885CTSB 527/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CTSL 941/4885CTSB 527/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CTSL 941/4885CTSB 527/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CTSL 941/4885CTSB 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.